Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten J Postma

Showing results (11-20 of 485) with videos related to

Pageof 49
Sort By:
Plos One|December 18, 2015
The Burden of Tick-Borne Encephalitis in Disability-Adjusted Life Years (DALYs) for SloveniaRenata Šmit, Maarten J Postma
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 12, 2021
Health Economics of Vaccines: From Current Practice to Future PerspectivesCornelis Boersma, Maarten J Postma
Human Vaccines & Immunotherapeutics|November 27, 2014
A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch childrenPepijn Vemer, Maarten J Postma
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 17, 2009
The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitusMaarten J Postma, Dick de Zeeuw
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?Jasper M Bos, Maarten J Postma
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrantRogier M Klok, Maarten J Postma
Human Vaccines & Immunotherapeutics|February 1, 2013
Economics of vaccines revisitedMaarten J Postma, Baudouin A Standaert
European Journal of Public Health|August 21, 2009
Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugsAnna K Lugnér, Maarten J Postma
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2009
Mitigation of pandemic influenza: review of cost-effectiveness studiesAnna K Lugnér, Maarten J Postma
BMC Public Health|December 3, 2013
Effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus immunization in IndonesiaAuliya A Suwantika, Maarten J Postma
Pageof 49

Showing results (11-20 of 485) with videos related to

Sort By:
Pageof 49
Plos One|December 18, 2015
The Burden of Tick-Borne Encephalitis in Disability-Adjusted Life Years (DALYs) for SloveniaRenata Šmit, Maarten J Postma
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 12, 2021
Health Economics of Vaccines: From Current Practice to Future PerspectivesCornelis Boersma, Maarten J Postma
Human Vaccines & Immunotherapeutics|November 27, 2014
A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch childrenPepijn Vemer, Maarten J Postma
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 17, 2009
The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitusMaarten J Postma, Dick de Zeeuw
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?Jasper M Bos, Maarten J Postma
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrantRogier M Klok, Maarten J Postma
Human Vaccines & Immunotherapeutics|February 1, 2013
Economics of vaccines revisitedMaarten J Postma, Baudouin A Standaert
European Journal of Public Health|August 21, 2009
Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugsAnna K Lugnér, Maarten J Postma
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2009
Mitigation of pandemic influenza: review of cost-effectiveness studiesAnna K Lugnér, Maarten J Postma
BMC Public Health|December 3, 2013
Effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus immunization in IndonesiaAuliya A Suwantika, Maarten J Postma
Pageof 49